Initiation Archives - Page 103 of 272

HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Poseida Therapeutics (NASDAQ:PSTX) with a Buy rating and announces Price Target of $15.

PSTX

1 minute read

New Street Research Initiates Coverage On Netflix with Neutral Rating, Announces Price Target of $304

By Benzinga Newsdesk

January 4, 5:52 AM

New Street Research analyst Dan Salmon initiates coverage on Netflix (NASDAQ:NFLX) with a Neutral rating and announces Price Target of $304.

NFLX

1 minute read

New Street Research Initiates Coverage On Match Group with Buy Rating, Announces Price Target of $54

By Benzinga Newsdesk

January 4, 5:50 AM

New Street Research analyst Dan Salmon initiates coverage on Match Group (NASDAQ:MTCH) with a Buy rating and announces Price Target of $54.

MTCH

1 minute read

New Street Research Initiates Coverage On Meta Platforms with Buy Rating, Announces Price Target of $145

By Benzinga Newsdesk

January 4, 5:47 AM

New Street Research analyst Dan Salmon initiates coverage on Meta Platforms (NASDAQ:META) with a Buy rating and announces Price Target of $145.

New Street Research Initiates Coverage On Alphabet with Buy Rating, Announces Price Target of $118

By Benzinga Newsdesk

January 4, 5:46 AM

New Street Research analyst Dan Salmon initiates coverage on Alphabet (NASDAQ:GOOGL) with a Buy rating and announces Price Target of $118.

GOOG

1 minute read

New Street Research Initiates Coverage On Amazon.com with Buy Rating, Announces Price Target of $130

By Benzinga Newsdesk

January 4, 5:44 AM

New Street Research analyst Dan Salmon initiates coverage on Amazon.com (NASDAQ:AMZN) with a Buy rating and announces Price Target of $130.

AMZN

1 minute read

SMBC Nikko Initiates Coverage On Okta with Outperform Rating, Announces Price Target of $90

By Benzinga Newsdesk

January 4, 5:41 AM

SMBC Nikko analyst Carson Sippel initiates coverage on Okta (NASDAQ:OKTA) with a Outperform rating and announces Price Target of $90.

OKTA

1 minute read

Oppenheimer Initiates Coverage On Icosavax with Outperform Rating, Announces Price Target of $27

By Benzinga Newsdesk

January 4, 5:40 AM

Oppenheimer analyst Hartaj Singh initiates coverage on Icosavax (NASDAQ:ICVX) with a Outperform rating and announces Price Target of $27.

ICVX